SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

CRMD

CorMedix, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong beat and raised guidance, combined with positive Phase III ReSPECT data, create a powerful catalyst. Monitor the sNDA submission timeline for REZZAYO in H2 2026 and the ongoing TPN study enrollment acceleration for further upside. The stock repurchase program and strong cash position provide downside support.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.93
T+0 close · May 14, 2026 · via day close
Latest settled
−5.04%
T+60 · $7.53
Vs SPY
−8.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $7.93entry
  2. T+1 · 6mo ago −4.79%α −3.56% · $7.55
  3. T+5 · 6mo ago +1.64%α +2.36% · $8.06
  4. T+20 · 5mo ago +10.21%α +11.07% · $8.74
  5. T+60 · 3mo ago −5.04%α −8.63% · $7.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 consensus), driven by strong DefenCath sales ($97.5M) and the acquired Melinta portfolio ($29.9M). The company raised full-year 2026 revenue guidance to $325-345M and adjusted EBITDA guidance to $115-135M, while also announcing positive Phase III ReSPECT trial results for REZZAYO prophylaxis, supporting a bullish outlook.

Key Financial Metrics

EPS
$0.43
est $0.33 · +30.3%
Revenue
$127.4M
est $105.0M · +21.3% · +226.0% YoY
Rating
strong beat
Guidance
$325M-$345M
raised
Gross Margin
82.5%

Key Facts

  • Q1 2026 net revenue $127.4M vs consensus $105.0M (beat by 21.3%)
  • GAAP diluted EPS $0.43 vs consensus $0.33 (beat by 30.3%)
  • DefenCath sales $97.5M, including $9.0M favorable change in estimate
  • Melinta portfolio contributed $29.9M in revenue
  • Net income $38.6M vs $20.6M in Q1 2025
  • Adjusted EBITDA $70.0M vs $23.6M in Q1 2025
  • Raised FY 2026 revenue guidance to $325-345M (from prior $310-330M)
  • Raised FY 2026 adjusted EBITDA guidance to $115-135M
  • Positive Phase III ReSPECT trial for REZZAYO prophylaxis; sNDA submission expected H2 2026
  • Cash and short-term investments $178.1M at quarter end

Financial Impact

Revenue beat consensus by $22.4M (21.3%); EPS beat by $0.10 (30.3%); guidance raised by $15M at midpoint

revenueepsadjusted ebitdaguidance

Risk Factors

  • Pending TDAPA expiration could pressure DefenCath revenue in future quarters
  • Non-recurring $9.0M favorable estimate adjustment inflated Q1 DefenCath sales
  • Integration and operating expense growth from Melinta acquisition (opex up 139% YoY)
  • Clinical trial execution risk for TPN study and REZZAYO sNDA approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294799

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026